Mitoxantrone
 |
|
10M053, 20 mg/10 ml/Viall現行藥物外觀
中文名:雙羥
廠牌:景德
|
|
| Product
name |
| Mitoxantrone / Novantrone |
|
| Dosage
form |
|
| Indications |
| Advanced hormone-refractory prostate carcinoma;
Multiple sclerosis;
Acute nonlymphocytic leukemia
|
|
| Administration
& Dosage |
|
Advanced hormone-refractory prostate carcinoma: IV infusion, over a short period of time, 12-14 mg/m2 every 21 days.
Multiple sclerosis: IV infusion, over 5-15 mins, 12 mg/m2 every 3 mo.
Acute nonlymphocytic leukemia: IV infusion,
Induction, 12 mg/m2/d on days 1-3, in combination with cytarabine 100 mg/m2/d as continuous IV infusion on days 1-7
Re-induction, if incomplete response to 1st induction, may give 2nd induction dose, 12 mg/m2/d for 2 days in combination with cytarabine 100 mg/m2/d as continuous IV infusion on days 1-5
Consolidation, 12 mg/m2/d on days 1 and 2, in combination with cytarabine 100 mg/m2/d as continuous IV infusion on days 1-5; the 1st course is usually started 6 wk after final induction dose and the 2nd, 4 wks after the 1st |
|
| Contraindication |
| hypersensitivity to mitoxantrone products. |
|
| Precaution |
|
| Adverse
reaction |
| M: Cough or shortness of breath; GI bleeding; leucopenia; stomach pain; stomatitis; amenorhea; asthenia; aphthosis; constipation; cutaneous mycosis; diarrhea; headache; menorrhagia; N/V; pharyngitis; rhinitis; URI; UTI; Blue-green urine; loss of hair
L: Arrhythmias; CHF; conjunctivitis; jaundice; renal failure; seizures; thrombocytopenia; blue color in whites of eyes
R: Allergic reaction; extravasation; local irritation or phlebitis
|
|
| Drug
Interaction |
|
| Pregnancy
Category |
|
| Notes |
Mitoxantrone
 |
| |
|
|
|
|
|
|
|
| Mitoxantrone
|
|
10M053, 20 mg/10 ml/Viall現行藥物外觀
中文名:雙羥
廠牌:景德
|
|
| Product
name |
| Mitoxantrone / Novantrone |
|
| Dosage
form |
|
| Indications |
| Advanced hormone-refractory prostate carcinoma;
Multiple sclerosis;
Acute nonlymphocytic leukemia
|
|
| Administration
& Dosage |
|
Advanced hormone-refractory prostate carcinoma: IV infusion, over a short period of time, 12-14 mg/m2 every 21 days.
Multiple sclerosis: IV infusion, over 5-15 mins, 12 mg/m2 every 3 mo.
Acute nonlymphocytic leukemia: IV infusion,
Induction, 12 mg/m2/d on days 1-3, in combination with cytarabine 100 mg/m2/d as continuous IV infusion on days 1-7
Re-induction, if incomplete response to 1st induction, may give 2nd induction dose, 12 mg/m2/d for 2 days in combination with cytarabine 100 mg/m2/d as continuous IV infusion on days 1-5
Consolidation, 12 mg/m2/d on days 1 and 2, in combination with cytarabine 100 mg/m2/d as continuous IV infusion on days 1-5; the 1st course is usually started 6 wk after final induction dose and the 2nd, 4 wks after the 1st |
|
| Contraindication |
| hypersensitivity to mitoxantrone products. |
|
| Precaution |
|
| Adverse
reaction |
| M: Cough or shortness of breath; GI bleeding; leucopenia; stomach pain; stomatitis; amenorhea; asthenia; aphthosis; constipation; cutaneous mycosis; diarrhea; headache; menorrhagia; N/V; pharyngitis; rhinitis; URI; UTI; Blue-green urine; loss of hair
L: Arrhythmias; CHF; conjunctivitis; jaundice; renal failure; seizures; thrombocytopenia; blue color in whites of eyes
R: Allergic reaction; extravasation; local irritation or phlebitis
|
|
| Drug
Interaction |
|
| Pregnancy
Category |
|
| Notes |
分類 |
藥號、藥名 |
建議處理方式 |
局部緩解劑 |
刺激/發?性-Anthracenedione |
Mitoxantrone |
間歇冰敷及抬高患肢。 |
|
|
|
| |